The production and wide use of artificial antigen presenting cells (aAPCs) in the clinic as
cancer immunotherapeutics are hindered by the need of identifying immunogenic cancer …

CD4+ helper T cells are critical for protective immune responses and yet suboptimally
primed in response to tumors. Cell-based vaccination strategies are under evaluation in …

Peptide recognition through the MHC class I molecule by cytotoxic T lymphocytes (CTL s)
leads to the killing of cancer cells. A potential challenge for T‐cell immunotherapy is that …

Antigen-presenting cells expand antigen-specific T cells ex vivo and in vivo for tumor
immunotherapy, but are time-consuming to generate and, as live cells, raise biosafety …

Because APCs play a crucial role in the generation of T cell-mediated immune responses,
numerous clinical trials with APC-based vaccines have been initiated in different types of …

Cancer cells and embryonic tissues share a number of cellular and molecular properties,
suggesting that induced pluripotent stem cells (iPSCs) may be harnessed to elicit anti-tumor …

Appropriate presentation of tumor-associated antigens (TAA) by antigen-presenting cells
(APC) is required for the development of clinically relevant antitumor T-cell responses. One …

Antigenic peptides play a central role in immune surveillance in cancer, infectious disease,
autoimmunity, and allergy. The identification and isolation of antigenic peptides for T cell …

Therapeutic cancer vaccination seeks to elicit activation of tumor-reactive T cells capable of
recognizing tumor-associated antigens (TAA) and eradicating malignant cells. Here, we …

Individualized cancer vaccines based on patient-specific neoantigens are a groundbreaking
approach in oncology, offering a highly individualized treatment option for cancer patients …